Case at a Glance
In January 2026, the Supreme Court held that stem cell therapy for Autism Spectrum Disorder (ASD) is not recognised medical practice and cannot be offered as a clinical service outside an approved and monitored research or trial setting. Reviewing compliance on 13 October 2026, the Court found that a ‘labyrinth’ of rules, office orders and advisories, together with a lack of readily accessible information, had allowed malpractice to continue. It directed the Union Health Ministry to publish a step-wise approval protocol and a public awareness section within six weeks, set up a portal for public views on a proposed ICMR trial within four weeks, and create a mandatory registry of existing patients within six weeks. Existing patients may continue temporarily at current clinics if registered, but no new patients may begin the therapy outside approved trials.
By its judgment of 30 January 2026, the Court held that stem cell therapy for ASD is not recognised as sound and relevant medical practice under current regulatory standards and cannot be offered as a clinical service outside an approved, monitored research or clinical trial setting, while leaving room for people to participate in approved trials as research subjects. On 1 September 2026, it asked the Union whether reasonable steps were being taken to move existing patients into a regulated research framework.
In a compliance affidavit dated 28 September 2026, the Union (through the Department of Health Research) stated that a National Stem Cell Research Regulation Committee (NSRC) had been constituted in March 2026; that circulars and advisories had been issued by the DHR, the National Medical Commission and the Health Ministry; that CDSCO, DHR and ICMR had received no application for stem cell trials for ASD; and that a six-month, ICMR-funded multicentre randomised controlled trial (RCT) was proposed at one site in North India and one in South India. Parents and guardians of children undergoing therapy, and a parents’ forum, also appeared.
The Key Question Before the Court
What steps must the Union take so that the bar on stem cell therapy for autism outside approved trials is clear to the public, and what happens to children already receiving it?
Not a Ruling on Science, but on Law and Transparency
The Court clarified that it was not deciding the scientific efficacy of stem cell therapy; the question was one of law under the existing regulatory framework. It reaffirmed that the therapy “cannot be offered as a clinical service outside an approved and monitored research/clinical trial setting”, and noted that the prohibition is not permanent — future rigorous research could lead regulators to reconsider.
The Court found that the ‘labyrinth’ of rules, office orders and advisories could allow malpractice to persist, and that the lack of readily accessible information had tacitly enabled it to continue. It also found the eligibility criteria for the proposed RCT unclear, especially whether randomisation could exclude those already on therapy. Balancing these concerns with the position of families already in treatment, it permitted temporary continuation under registration and monitoring while shutting the door on new patients outside trials. The order cites no precedents.
What the Court Actually Held
- The Health Ministry must, within six weeks, issue a step-wise protocol on the approval pathway for stem cell research and trials for ASD, with timelines, responsible authorities, legal basis and, where practicable, a flowchart, and must publish public-awareness material distinguishing established from experimental treatments.
- Within four weeks the Union must set up an online portal for public views on the proposed RCT, to be considered by the NSRC; within six weeks it must create a secure portal registering existing patients (those who began on or before 30 January 2026) and their doctors.
- Existing patients may continue therapy at current clinics, subject to registration and monitoring, until the proposed tertiary care centres are operational; this is not an approval of the therapy.
- No new patient may begin stem cell therapy for ASD outside an approved and monitored research or trial setting; the Union must explain the RCT eligibility criteria at the next hearing on 14 December 2026.
Why This Judgment Matters
- It gives families of children with autism a clear, official source on what is and is not legally permitted.
- It curbs clinics that market unproven stem cell ‘cures’ outside regulated trials.
- It balances regulatory discipline with continuity of care for children already under treatment.
What Should Advocates Take Away From the Judgment?
For Parents and Patients
- Do not start a child on stem cell therapy for autism outside an approved trial; it is not permitted.
- If your child began therapy on or before 30 January 2026, register on the portal once it is set up to continue temporarily.
- Use the public views portal to give inputs on the proposed ICMR trial.
For Doctors and Counsel
- Treating doctors must register before continuing therapy for existing patients.
- Advertising or offering the therapy outside approved trials runs against the Court’s binding directions.
- Track the protocol and RCT eligibility criteria the Union must place on record by the next hearing.
Key Takeaways
- Stem cell therapy for autism cannot be offered as clinical treatment outside approved, monitored trials.
- No new patients may begin the therapy outside such trials.
- Existing patients may continue temporarily only after mandatory registration.
- The Health Ministry must publish a clear protocol and awareness material within six weeks.
Frequently Asked Questions
Has the Supreme Court said stem cell therapy does not work for autism?
No. The Court made clear it is not deciding scientific efficacy; it held that under the current regulatory framework the therapy cannot be offered as a clinical service outside approved trials.
My child was already receiving therapy. What now?
Patients who began on or before 30 January 2026 may continue at their current clinics on a temporary basis, subject to registration on the patient portal and monitoring, until the tertiary care centres are operational.
Can a new patient join?
Only through an approved and monitored research or clinical trial; starting the therapy elsewhere is barred.
Conclusion
The Supreme Court has turned its January ruling into a concrete compliance plan: clearer rules, public information, a patient registry and a consultative trial process, so that families are not left to navigate an opaque system or unregulated clinics.
Practical takeaway: Families considering stem cell therapy for autism should look only to approved trials, and those already in treatment should register as soon as the portal goes live.
For more judgments, legal opinions and case analysis, visit courtkutchehry.com